Neurokine Pharmaceuticals Inc. (OTCBB: NEUKF) is pleased to announce
the appointment of Moira Ong, CA, CFA, to position of Chief Financial
Officer. Ms. Ong has more than 10 years experience in public company
accounting and audit reporting. From 2005 until 2010, Ms. Ong was the
senior Manager at Grant Thornton, LLP in charge of completion of
financial statements for Canadian publicly listed companies. From 2003
to 2005 she served as Financial Consultant for strategic Income
Security Services. Ms. Ong was the manager of Banking and Securities
at Deloitte & Touche LLP in New York from 2000 to 2003 and served as
the Senior Accountant for Grant Thornton LLP from 1996 to 2000. Ms.
Ong obtained her CA designation in 1999 and her CFA designation in
2003.
About Neurokine
Neurokine Pharmaceuticals Inc. focuses on development of new use for
existing marketed products for diseases mediated by acute and chronic
inflammatory reactions. The company is developing proprietary
encapsulation technology to allow better blood brain barrier
penetration to initiate or enhance therapeutic effects of
anti-inflammatory drugs in the treatment of neurodegenerative
diseases.
Safe Harbor Statement:
Except for historical information contained herein, the matters set
forth above may be forward-looking statements that involve certain
risks and uncertainties that could cause actual results to differ from
those in the forward-looking statements. Words such as "anticipate",
"believe", "estimate", "expect", "intend" and similar expressions, as
they relate to Neurokine or its management, identify forward-looking
statements. Such forward-looking statements are based on the current
beliefs of management, as well as assumptions made by and information
currently available to management. Actual results could differ
materially from those contemplated by the forward-looking statements
as a result of certain factors such as the level of business and
consumer spending, the amount of sales of Neurokine's products, the
competitive environment within the industry, the ability of Neurokine
to continue to expand its operations, the level of costs incurred in
connection with Neurokine's expansion efforts, economic conditions in
the industry and the financial strength of Neurokine's customers and
suppliers. Neurokine does not undertake any obligation to update such
forward-looking statements. Investors are also directed to consider
all other risks and uncertainties.